Keywords: Multiple sclerosis treatments, US neurologists, Biogen Idec, Elan, Tysabri, Gilenya, Avonex, BG-12, Decision Resources

US neurologists' adoption of STRATIFY JCV has shifted Tysabri earlier in the treatment of some MS patients

Article | 15 August 2012

Print This

In the USA, 77% of surveyed neurologists have experience with the STRATIFY JCV assay - commercially available since January 2012 to aid ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in